Tempus reported preliminary, unaudited revenue of approximately $1.27 billion for full year 2025, an 83 percent increase over 2024, including roughly 30 percent organic growth excluding Ambry. Diagnostics revenue reached about $955 million, up 111 percent year-over-year, driven by oncology test volume growth of 26 percent and hereditary test volume growth of 29 percent. Data and applications revenue totaled $316 million, a 31 percent rise, led by a 38 percent increase in data licensing. In the fourth quarter, Tempus generated roughly $367 million in revenue, mirroring 83 percent year-over-year growth. Diagnostics revenue of $266 million surged 121 percent, with oncology volume up 29 percent and hereditary volume up 23 percent. Data and applications revenue in Q4 was $100 million, a 25 percent increase, with insights licensing growing 68 percent after adjusting for the AstraZeneca warrant in Q4 2024.

As of December 31, 2025, Tempus achieved a record Total Contract Value of more than $1.1 billion. During the year, the company signed data agreements with over 70 customers across large and mid-sized pharmaceutical firms, including leading names such as AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Pfizer, Novartis, Merck, AbbVie, Daiichi Sankyo, Eli Lilly and Boehringer Ingelheim, as well as numerous biotech partners. This expanded contract backlog underscores the growing demand for Tempus’s AI-enabled precision medicine solutions and strengthens the company’s revenue visibility heading into 2026.